Monoclonal antibodies recognizing bevacizumab and uses thereof
By preparing anti-Avastin monoclonal antibodies with specific CDR sequences and enzymatically digesting them to prepare the F(ab')2 fragment, the problems of insufficient specificity and neutralizing activity in existing technologies have been solved, and efficient bevacizumab detection and evaluation have been achieved.
Patent Information
- Application Number
- CN202611287164.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-24
- Publication Date
- 2026-11-10
AI Technical Summary
Existing technologies lack highly specific anti-Avastin monoclonal antibodies with strong competitive neutralizing activity against VEGF, leading to distorted quantitative results and making them unsuitable for the construction of neutralizing antibody detection systems.
A monoclonal antibody against avastin is provided, which contains specific heavy and light chain variable region (CDR) sequences that can specifically bind to and neutralize VEGF, blocking tumor angiogenesis. The F(ab')2 fragment is prepared by pepsin digestion, and a monoclonal antibody that highly recognizes bevacizumab is prepared by hybridoma cells.
It achieves high specific binding and neutralizing activity, can specifically recognize bevacizumab and its fragments, avoids cross-reaction with human endogenous plasma IgG, and is suitable for preclinical pharmacology, pharmacokinetics and immunogenicity evaluation of bevacizumab.
Smart Images

Figure CN123062579A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of antibody technology, specifically relating to monoclonal antibodies that recognize bevacizumab and their applications. Background Technology
[0002] Avastin, a classic therapeutic monoclonal antibody targeting VEGF, requires key trials in its preclinical pharmacology, clinical pharmacokinetics, and immunogenicity evaluation stages. These trials include free drug quantification, anti-drug binding antibody detection, and anti-drug neutralizing antibody screening. These trials heavily rely on anti-idiotypic monoclonal antibodies possessing both specific binding activity and competitive neutralizing activity against VEGF as standard positive controls. Existing commercially available anti-Avastin antibody raw materials and research-grade paired antibodies suffer from several unavoidable technical shortcomings: 1) Commercially available conventional anti-bevacizumab antibodies target multiple constant regions, which can only achieve simple binding capture and do not have competitive neutralizing activity, so they cannot be used to build a neutralizing antibody detection system; 2) A few anti-idiotype antibodies with neutralizing competitive ability have poor specificity and are prone to cross-reaction with human endogenous plasma IgG and other isotype therapeutic monoclonal antibodies, resulting in severe matrix interference and distorted quantitative results.
[0003] In summary, existing technologies lack a highly specific anti-Avastin idiotype monoclonal antibody with potent VEGF competitive neutralizing activity. This invention addresses these deficiencies by providing a method for preparing and a detection system for an anti-Avastin idiotype monoclonal antibody that possesses both specific binding and neutralizing activity, filling a gap in industry tools and reagents. Summary of the Invention
[0004] In view of this, in order to overcome the shortcomings of the prior art, the present invention is proposed.
[0005] A first aspect of the present invention provides an antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof, said antibody or antigen-binding fragment comprising a heavy chain variable region and a light chain variable region, said heavy chain variable region and light chain variable region having a) The amino acid sequences of heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 in the heavy chain variable region as shown in SEQ ID NO:1; The amino acid sequences are as shown in SEQ ID NO:2, specifically the light chain CDR1, CDR2, and CDR3 in the light chain variable region; or b) The amino acid sequences of heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 in the heavy chain variable region as shown in SEQ ID NO:11; The amino acid sequences are shown in SEQ ID NO:12, specifically light chain CDR1, light chain CDR2, and light chain CDR3 in the light chain variable region.
[0006] Bevacizumab (Avastin) is a humanized monoclonal antibody drug that targets human vascular endothelial growth factor (VEGF). Its core function is to specifically bind to and neutralize VEGF, thereby blocking tumor angiogenesis. It is widely used in the treatment of malignant tumors and fundus diseases such as colorectal cancer, lung cancer, ovarian cancer, and fundus neovascularization.
[0007] In some implementations, the bevacizumab fragment includes, but is not limited to, fragments that retain the bevacizumab binding activity with VEGF.
[0008] In some embodiments, the bevacizum fragment includes a heavy chain variable region and / or a light chain variable region.
[0009] In some implementations, the bevacizum fragments include, but are not limited to, Fab, Fab', F(ab)'2, scFv, or VHH.
[0010] In some embodiments, the bevacizum fragment is selected from bevacizum F(ab)'2.
[0011] Those skilled in the art can determine, using conventional methods, the heavy chain CDR1, heavy chain CDR2, heavy chain CDR3 and light chain CDR1, light chain CDR2, and light chain CDR3 contained in the heavy chain variable region and light chain variable region according to the heavy chain variable region and antigen-binding fragment of the antibody or antigen-binding fragment that recognizes bevacizum or its fragments, provided by the present invention. CDRs determined by different methods all fall within the scope of protection of this application. For example, the IMGT method, Kabat method, AbM method, Chothia method, or Contact method can be used to define the CDRs in the amino acid sequence of the variable region.
[0012] In some embodiments, the amino acid sequences of the heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 are shown in SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, respectively, and the amino acid sequences of the light chain CDR1, light chain CDR2, and light chain CDR3 are shown in SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, respectively; or The amino acid sequences of the heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 are shown in SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, respectively, and the amino acid sequences of the light chain CDR1, light chain CDR2, and light chain CDR3 are shown in SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, respectively.
[0013] In some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment recognizing bevacizum or a fragment thereof has an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the amino acid sequence shown in SEQ ID NO:1; and the light chain variable region of the antibody or antigen-binding fragment recognizing bevacizum or a fragment thereof has an amino acid sequence as shown in SEQ ID NO:2 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the amino acid sequence shown in SEQ ID NO:2; or The heavy chain variable region of the antibody or antigen-binding fragment that recognizes bevacizumab or its fragments has an amino acid sequence as shown in SEQ ID NO:11 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence shown in SEQ ID NO:11. The light chain variable region of the antibody or antigen-binding fragment that recognizes bevacizumab or its fragments has an amino acid sequence as shown in SEQ ID NO:12 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence shown in SEQ ID NO:12.
[0014] In some implementations, the antigen-binding fragments include, but are not limited to, Fab, Fab′, F(ab′)2, single-chain antibody scFv, and nanobody VHH.
[0015] In some implementation schemes, the antibody can be a non-human antibody, a chimeric antibody, a humanized antibody, or a fully human antibody.
[0016] In some implementations, the antibody can be a monospecific antibody or a multispecific antibody.
[0017] In some implementations, multispecific antibodies include bispecific antibodies, trispecific antibodies, tetraspecific antibodies, or even more specific antibodies.
[0018] In some implementations, the antibody can be a monoclonal antibody, a polyclonal antibody, or a recombinant antibody.
[0019] In some embodiments, the antibody also includes a constant region, which, depending on its structure, includes IgG antibodies, IgA antibodies, IgM antibodies, IgE antibodies, and IgD antibodies.
[0020] In some embodiments, the heavy chain constant region of the antibody is the IgG1 subtype, and the light chain constant region is the κ type.
[0021] The second aspect of the present invention provides an antibody derivative formed by direct or indirect coupling of a detectable marker with an antibody or antigen-binding fragment that recognizes bevacizum or a fragment thereof as described in the first aspect of the present invention.
[0022] In this invention, the term "detectable marker" refers to a reagent that is detectable, for example, by spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
[0023] In some implementations, the detectable markers include, but are not limited to, radionuclides, chemiluminescent agents, bioluminescent agents, paramagnetic ions, enzymes, and photosensitizing diagnostic agents.
[0024] In some embodiments, the radionuclides include, but are not limited to, those mentioned above. 18 F, 52 Fe、 62 Cu、 64 Cu、 67 Cu、 86 Y、 90 Y、 89 Zr、 120 I, 123 I, 124 I, 125 I, 131 I, 13 N、 15 O、 186 Re、 188 Re、 51 Mn, 55 Co、 72 As.
[0025] In some embodiments, the chemiluminescent agent includes, but is not limited to, luminol, isoluminol, aromatic acridine esters, imidazole, acridine salts, and oxalates.
[0026] In some embodiments, the bioluminescent agent includes, but is not limited to, luciferin, luciferase, and jellyfish luminescent protein.
[0027] In some embodiments, the paramagnetic ions include, but are not limited to, chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III), and erbium (III).
[0028] In some embodiments, the enzyme includes, but is not limited to, horseradish peroxidase, alkaline phosphatase, glucose oxidase, β-D-galactosidase, urease, catalase, or glucosylamylase.
[0029] In some embodiments, the photosensitive diagnostic agent includes, but is not limited to, dihydroxysilyl phthalocyanine, methylene blue, protoporphyrin, hematoporphyrin, and photoporphyrin.
[0030] A third aspect of the invention provides hybridoma cells that produce antibodies or antigen-binding fragments that recognize bevacizum or fragments thereof as described in the first aspect of the invention.
[0031] A fourth aspect of the present invention provides a polynucleotide molecule that encodes an antibody or antigen-binding fragment that recognizes bevacizum or a fragment thereof as described in the first aspect of the present invention.
[0032] "Polynucleotide" includes, but is not limited to, single-stranded and double-stranded DNA, DNA consisting of a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA, and RNA consisting of a mixture of single-stranded and double-stranded regions, and hybrid molecules comprising DNA and RNA that may be single-stranded or more typically double-stranded, or a mixture of single-stranded and double-stranded regions. Additionally, "polynucleotide" refers to a triple-stranded region comprising RNA or DNA, or both RNA and DNA. The term polynucleotide also includes DNA or RNA containing one or more modified bases, and DNA or RNA having a backbone modified for stability or other reasons.
[0033] In this invention, the polynucleotide molecule may comprise natural, non-natural, or modified nucleotides; and it may comprise natural, non-natural, or modified internucleotide linkages, such as aminophosphate linkages or thiophosphate linkages, instead of phosphodiesters present between the nucleotides of the unmodified oligonucleotide.
[0034] In some embodiments, the nucleotide does not contain any insertions, deletions, inversions, and / or substitutions. However, in some cases, it may be suitable for a nucleotide to contain one or more insertions, deletions, inversions, and / or substitutions, and therefore, nucleotides formed by these insertions, deletions, inversions, and / or substitutions are also within the scope of protection of this invention.
[0035] In some embodiments, the polynucleotide molecule contains a nucleotide sequence as shown in SEQ ID NO:9, SEQ ID NO:10, or a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the nucleotide sequence shown in SEQ ID NO:9, SEQ ID NO:10.
[0036] In some embodiments, the polynucleotide molecule contains a nucleotide sequence as shown in SEQ ID NO:19, SEQ ID NO:20, or a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the nucleotide sequences shown in SEQ ID NO:19, SEQ ID NO:20.
[0037] The fifth aspect of the present invention provides a carrier containing the polynucleotide molecule described in the fourth aspect of the present invention.
[0038] Examples of vectors that can be used in this invention include, but are not limited to: plasmids, phage particles, granules, artificial chromosomes, and virus-derived vectors.
[0039] Various vectors known in the art can be used, such as commercially available vectors, and then the polynucleotide encoding the antibody or its antigen-binding fragment can be operatively linked to the expression regulatory sequence to form an expression vector. Further, the virus-derived vectors include, but are not limited to: lentiviral vectors, retroviral vectors, adenovirus vectors, adeno-associated virus vectors, poxvirus vectors, herpesvirus vectors, baculovirus vectors, papillomavirus vectors, and papillomavirus vectors.
[0040] In some embodiments, the expression vector may contain expression regulatory sequences, such as transcription and translation start and stop codons, which are specific to the type of host cell (e.g., bacteria, fungi, plants, or animals) into which the vector is to be introduced, depending on the circumstances and whether the vector is DNA-based or RNA-based. Recombinant expression vectors may contain restriction sites to facilitate cloning.
[0041] In some embodiments, the vector may also contain one or more marker genes that allow selection of host cells for transformation or transfection. Marker genes include biocidal resistance (e.g., resistance to antibiotics, heavy metals, etc.); prototrophic complementation in auxotrophic hosts, etc. Suitable marker genes for the expression vector of the present invention include, for example, neomycin / G418 resistance genes, hygromycin resistance genes, histidine resistance genes, tetracycline resistance genes, ampicillin resistance genes, kanamycin resistance genes, and puromycin resistance genes.
[0042] The sixth aspect of the present invention provides a host cell or a cell population comprising a host cell, said host cell comprising an antibody or antigen-binding fragment that recognizes bevacizum or a fragment thereof as described in the first aspect of the present invention, a polynucleotide molecule as described in the fourth aspect of the present invention, or a vector as described in the fifth aspect of the present invention.
[0043] As used herein, the term "host cell" or "population of cells containing host cells" or related terms include cells (or populations or multiple host cells) to which a foreign (exogenous or transgenic) nucleic acid has been introduced. The foreign nucleic acid may include an expression vector operatively linked to a transgene, and the host cell may be used to express the nucleic acid and / or a polypeptide encoded by the foreign nucleic acid (transgene). The host cell (or population thereof) may be cultured cells or may be extracted from an individual. The host cell (or population thereof) includes primary cells of an individual and their progeny, regardless of passage number. The host cell (or population thereof) includes immortalized cell lines. Progeny cells may or may not contain the same genetic material as the parent cells. The term "host cell" encompasses progeny cells. In one embodiment, "host cell" describes any cell (including its progeny) that has been modified, transfected, transduced, hosted, and / or manipulated in any way to express an antibody, as disclosed herein. In one instance, an expression vector operatively linked to a nucleic acid, as described herein, encoding a desired antibody or an antigen-binding fragment thereof, may be introduced into a host cell (or population thereof).
[0044] In some implementations, the host cell may be a prokaryote, such as Escherichia coli, or may be a eukaryote, such as a single-celled eukaryote (e.g., yeast or other fungi), a plant cell (e.g., tobacco or tomato plant cells), a mammalian cell (e.g., human cells, monkey cells, hamster cells, rat cells, mouse cells, or insect cells), or a hybridoma.
[0045] The seventh aspect of the present invention provides a product for detecting or quantifying bevacizum or a fragment thereof, said product containing an antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in the first aspect of the present invention, an antibody derivative as described in the second aspect of the present invention, hybridoma cells as described in the third aspect of the present invention, a polynucleotide molecule as described in the fourth aspect of the present invention, a vector as described in the fifth aspect of the present invention, and a host cell or a cell population containing a host cell as described in the sixth aspect of the present invention.
[0046] In some implementations, the antibody or antigen-binding fragment that identifies bevacizumab or a fragment thereof is used as a standard positive control antibody, a capture antibody, or a detection antibody.
[0047] In some implementations, the products include, but are not limited to, reagent kits, test strips, reagents, and chips.
[0048] In some embodiments, the kit may also include, but is not limited to, a container for holding an antibody or antigen-binding fragment that recognizes bevacizum or a fragment thereof when not in use, instructions for use, an antibody or antigen-binding fragment that recognizes bevacizum or a fragment thereof attached to a solid support, a known standard, and a reference sample, or one or more of these.
[0049] The term "known standard" can be a solution containing a known amount or concentration of bevacizum or a fragment thereof, wherein such solution can be a naturally occurring solution; or such solution can be a synthetic solution, such as a buffered aqueous solution in which a known amount of bevacizum or a fragment thereof is diluted. Known standards described herein may include recombinant or purified bevacizum or fragment thereof protein isolated from subjects.
[0050] The term "reference sample" is a sample that can be compared with another sample, such as a test sample, to characterize the sample being compared. The reference sample will have certain characteristic properties as the basis for comparison with the test sample.
[0051] In some implementations, the kits include, but are not limited to, ELISA kits, immunofluorescence kits, FACS kits, Western Blot kits, IHC kits, and ICC kits.
[0052] The eighth aspect of the present invention provides any of the following methods: (1) An antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in the first aspect of the present invention, the method comprising the following steps: culturing hybridoma cells as described in the third aspect of the present invention, or host cells or a population of host cells containing the host cells as described in the sixth aspect of the present invention; (2) A method for detecting or quantifying bevacizum or a fragment thereof in a sample, the method comprising the following steps: contacting the sample to be tested with an antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in the first aspect of the present invention, or contacting the sample to be tested with an antibody derivative as described in the second aspect of the present invention, or contacting the sample to be tested with bevacizum or a fragment thereof for detection or quantification as described in the seventh aspect of the present invention, to form an antigen-antibody complex, and detecting the antigen-antibody complex. (3) A method for preparing the host cell or host cell population containing the sixth aspect of the present invention, the method comprising the following steps: introducing the polynucleotide molecule of the fourth aspect of the present invention or the vector of the fifth aspect of the present invention into the host cell; (4) A method for blocking the binding of bevacizumab to VEGF in vitro, the method comprising using an antibody or antigen-binding fragment for recognizing bevacizumab or a fragment thereof as described in the first aspect of the present invention, an antibody derivative as described in the second aspect of the present invention, or a product for detecting or quantifying bevacizumab or a fragment thereof as described in the seventh aspect of the present invention to block the binding of bevacizumab to VEGF. (5) A method for in vitro detection of bevacizumab antibody or fragment antibody for non-disease diagnostic purposes, the method comprising: contacting a sample with bevacizumab or fragment to form an immune complex; and detecting the presence or content of the immune complex; wherein the method uses the antibody or antigen-binding fragment for recognizing bevacizumab or fragment as described in the first aspect of the present invention, the antibody derivative as described in the second aspect of the present invention, and the product for detecting or quantifying bevacizumab or fragment as described in the seventh aspect of the present invention as a standard positive control.
[0053] The ninth aspect of the present invention provides any of the following applications: (1) The use of the antibody or antigen-binding fragment for recognizing bevacizum or its fragments as described in the first aspect of the present invention, the antibody derivative as described in the second aspect of the present invention, the hybridoma cell as described in the third aspect of the present invention, the polynucleotide molecule as described in the fourth aspect of the present invention, the vector as described in the fifth aspect of the present invention, the host cell or cell population containing the host cell as described in the sixth aspect of the present invention in the preparation of products for detecting or quantifying bevacizum or its fragments. (2) The use of the antibody or antigen-binding fragment for recognizing bevacizum or its fragments as described in the first aspect of the present invention, the antibody derivative as described in the second aspect of the present invention, the hybridoma cell as described in the third aspect of the present invention, the polynucleotide molecule as described in the fourth aspect of the present invention, the vector as described in the fifth aspect of the present invention, the host cell or cell population containing the host cell as described in the sixth aspect of the present invention, and the product for detecting or quantifying bevacizum or its fragments as described in the seventh aspect of the present invention in detecting or quantifying bevacizum or its fragments. (3) The application of the antibody or antigen-binding fragment for recognizing bevacizumab or its fragments as described in the first aspect of the present invention, the antibody derivative as described in the second aspect of the present invention, the hybridoma cell as described in the third aspect of the present invention, the polynucleotide molecule as described in the fourth aspect of the present invention, the vector as described in the fifth aspect of the present invention, the host cell or cell population containing the host cell as described in the sixth aspect of the present invention, and the product for detecting or quantifying bevacizumab or its fragments as described in the seventh aspect of the present invention in the preclinical pharmacological evaluation, pharmacokinetic evaluation and / or immunogenicity evaluation of bevacizumab monoclonal antigen research, biosimilar or modified derivative; Furthermore, the applications include, but are not limited to, quantification of free drugs and screening for neutralizing antibodies; (4) The use of the antibody or antigen-binding fragment for recognizing bevacizumab or its fragments as described in the first aspect of the present invention, the antibody derivative as described in the second aspect of the present invention, the hybridoma cell as described in the third aspect of the present invention, the polynucleotide molecule as described in the fourth aspect of the present invention, the vector as described in the fifth aspect of the present invention, the host cell or cell population containing the host cell as described in the sixth aspect of the present invention, and the product for detecting or quantifying bevacizumab or its fragments as described in the seventh aspect of the present invention in the preparation of a reagent for blocking the binding of bevacizumab to VEGF. (5) The use of the antibody or antigen-binding fragment for recognizing bevacizum or its fragments as described in the first aspect of the present invention, the antibody derivative as described in the second aspect of the present invention, and the product for detecting or quantifying bevacizum or its fragments as described in the seventh aspect of the present invention in the preparation of a product for detecting or quantifying bevacizum antibody or its fragment antibody, characterized in that the antibody or antigen-binding fragment for recognizing bevacizum or its fragments, the antibody derivative, and the product for detecting or quantifying bevacizum or its fragments are used as a positive control.
[0054] The advantages and beneficial effects of this invention are as follows: The antibody of this invention is an anti-idiotypic monoclonal antibody obtained by immunizing non-human mammals with the F(ab)'2 fragment of bevacizumab as an immunogen. Its specific idiotypic epitope is located in the heavy chain variable region and / or light chain variable region of bevacizumab, possessing the following three properties: (1) Specific binding activity: It can specifically bind to full-length bevacizumab and its F(ab')2 fragment, Fab fragment, etc.; (2) Strong VEGF competitive neutralizing activity: It can compete with VEGF to bind to the VEGF binding site of bevacizumab, inhibiting the binding of VEGF to bevacizumab, thereby neutralizing the VEGF binding activity of bevacizumab; (3) High specificity: It does not cross-react with endogenous human plasma immunoglobulin G or other isotype therapeutic monoclonal antibodies. Anti-idiotypic monoclonal antibodies possessing the above three properties have not been reported in the prior art. This invention fills the industry gap in tools and reagents for the pharmacological evaluation of bevacizumab. Attached Figure Description
[0055] Figure 1 This is an electrophoresis image of Avastin digested with pepsin (13% SDS-PAGE reducing gel). Lane 1: Protein molecular weight marker; Lane 2: Sample after Avastin digestion; Lane 3: Sample before Avastin digestion. Figure 2 This is the result of antibody pairing for 12B12E10A5; Figure 3 This is the result of 8G2H6A7 antibody pairing. Detailed Implementation
[0056] The present invention will be further described below with reference to embodiments. The following description is merely a preferred embodiment of the present invention and is not intended to limit the invention in any other way. Any person skilled in the art may make equivalent modifications to the disclosed technical content to create equivalent embodiments. Any simple modifications or equivalent changes made to the following embodiments based on the technical essence of the present invention without departing from the scope of the invention are all within the protection scope of the present invention.
[0057] Example 1: AVASTIN, F(ab)'2 fragment obtained by enzyme digestion and purification. 1. The experimental materials are shown in Table 1 below.
[0058] Table 1 Experimental Materials
[0059] 2. Experimental Methods Avastin antibody was digested with pepsin. Under specific acidic pH conditions, pepsin specifically cleaves the hinge region of the antibody near the Fc end. Because the disulfide bonds connecting the two heavy chains are preserved, the two Fab arms remain connected, forming a complete, divalent F(ab')2 fragment. The Fc region is then further digested into smaller peptides. Detailed steps are as follows: Take Avastin and add pepsin at a protein-to-enzyme mass ratio of 100:1. Incubate in sodium acetate buffer at pH 4.0 at 37°C for 20–24 h for enzyme digestion. Terminate the reaction by adding 10–20 mL of 2M pH 8.0 Tris-HCl buffer. Strictly monitor protein concentration and pH during the experiment.
[0060] After enzyme digestion, 10 μl of sample was taken and subjected to gel electrophoresis using a 13% SDS-PAGE reducing gel to detect the enzyme digestion effect. Under reducing conditions, the undigested sample mainly consisted of heavy and light chains of approximately 50 and 25 KD, respectively. The digested sample mainly consisted of light chains of approximately 25 KD and heavy chains >25 KD (VH+CH1+ hinges).
[0061] (4) F(ab)'2 was purified using a Protein A affinity chromatography column to remove excess large Fc fragments. The chromatographically purified sample was then ultrafiltered and centrifuged at approximately 4500 rpm using a 30 kDa ultrafiltration tube. The buffer was changed three times with phosphate-buffered saline (PBS) buffer, and finally resuspended in 2–10 mL of buffer as needed. This step concentrates the sample while removing protein fragments smaller than 30 kDa that have been cleaved by trypsin.
[0062] 3. Experimental Results Avastin samples before and after pepsin digestion were identified using a 13% separating gel SDS-PAGE reduction electrophoresis system. Before digestion, Avastin samples showed two clear bands at 40-50 KD and below 25 KD, consistent with the molecular weight characteristics of the heavy and light chains after IgG monoclonal antibody reduction, with no obvious impurity bands. After pepsin digestion, two clear bands appeared, indicating that pepsin successfully digested the Fab region of Avastin, achieving effective fragmentation of the antibody molecule. Detailed electrophoresis results are available in [link to detailed electrophoresis results]. Figure 1 .
[0063] Example 2: Immunization of Experimental Animals 1. Experimental Materials 1) SPF-grade female BALB / c mice, 6-8 weeks old (Beijing Vital River Laboratory Animal Technology Co., Ltd.); 2) Freund's complete adjuvant (Suzhou Bio-Long Technology Co., Ltd., item number: KX0210046Q), Freund's incomplete adjuvant (Suzhou Bio-Long Technology Co., Ltd., item number: KX0210047Q). 3) ELISA detection system: Coating solution (self-prepared), PBST washing solution (self-prepared), blocking solution (self-prepared), HRP-labeled goat anti-mouse IgG secondary antibody (Beijing Yiqiao Shenzhou Technology Co., Ltd., catalog number: SSA006), TMB chromogenic solution (self-prepared), stop solution (self-prepared). 2. Experimental Methods 1) Initial immunization (Day 0) Five BALB / c mice were immunized, with each mouse receiving a total immunization dose of 10 μg of enzyme-digested Avastin F(ab)'2 fragment. The protein solution was thoroughly emulsified by vortexing with an equal volume of Freund's complete adjuvant. The emulsion was deemed adequate when a drop of water was dropped into it and the liquid did not spread. The total emulsion volume was 100 μL, which was injected subcutaneously at 3-4 points in the neck, back, and groin of the mice.
[0064] 2) Second booster immunization (day 14) 10 μg of enzyme-digested Avastin F(ab)'2 fragment was emulsified with an equal volume of Freund's incomplete adjuvant, and 100 μL of the emulsified antigen was injected subcutaneously at multiple sites, following the same procedure as the first immunization.
[0065] 3) Three booster immunizations (on day 28) The same dose of FIA emulsified antigen was injected subcutaneously; on day 7 (day 35) post-immunization, 50-100 μL of blood was collected from the tail vein, the serum was separated, and the serum antibody titer was measured by indirect ELISA.
[0066] Serum antibody titer detection Add 100 μL of coating buffer (final protein concentration 1 μg / mL) to each well of a 96-well microplate and coat overnight at 4°C; wash three times with PBST for 3 min each time; add 300 μL of 2% skim milk blocking buffer to each well and incubate at room temperature for 1 h, then wash three times; add serially diluted serum samples: starting with 1:100, dilute 4-fold, 100 μL per well; set up a blank control group (PBS) and a negative mouse serum control; incubate at room temperature for 1.5 h, then wash three times; after washing, add 100 μL of HRP-labeled goat anti-mouse IgG secondary antibody diluted 1:20000 per well, incubate at room temperature for 1 h, then wash three times; add 100 μL of TMB chromogenic buffer to each well and develop at room temperature in the dark for 10-20 min; stop the reaction with 50 μL of 2 M H2SO4, and read the OD value at 450 nm using a microplate reader; 3. Experimental Results The serum of mice after three immunizations was detected by ELISA. The results showed that the serum titers of all five animals were greater than 200,000 times. Animals #1 and #2 had higher titers. The spleen of animal #1 was selected for fusion to prepare hybridoma cells.
[0067] Table 2. Results of serum titer detection in mice after Avastin F(ab)'2 fragment 3-immunization.
[0068] Example 3: Cell Fusion and Monoclonal Screening 1. Experimental Materials 1) SP2 / 0 myeloma cells (Suzhou Bio-Long Technology Co., Ltd.); 2) 6-8 week old SPF-grade female BALB / c mice (Beijing Vital River Laboratory Animal Technology Co., Ltd.) 3) 1640 medium (Gibco, catalog number: 11875119); HAT complete medium (Gibco, catalog number: 21060017); PEG4000 (Solepro, Cat: IP9100); Red blood cell lysis buffer (Solepro, Cat: R1010) 2. Experimental Methods 2.1. Preparatory work before integration 1) SP2 / 0 myeloma cell preparation: Resuscitate and passage 3 days before fusion, maintain logarithmic growth phase, viability >95%; collect on the day of fusion, wash twice with serum-free 1640 for use; 2) Feeder cell plating: One day before fusion, blank BALB / c mouse peritoneal macrophages were collected, resuspended in HAT complete medium, and plated in 96-well plates. They were then cultured overnight at 37°C with 5% CO2. 3) Reagent preheating: 50% PEG4000 and serum-free RPMI1640 culture medium were preheated in a 37°C water bath.
[0069] 2.2. Splenic lymphocyte isolation (high-titer immunization of mice) 1) Three days after the initial immunization, the mice were euthanized by cervical dislocation and their entire bodies were disinfected with 75% alcohol. 2) The spleen was removed aseptically, the adipose tissue was removed, and it was placed in a serum-free culture medium; 3) Gently grind the spleen with a cell sieve to prepare a single-cell suspension, centrifuge to remove the supernatant; lyse the red blood cells with red blood cell lysis buffer, stop the lysis with culture medium, wash twice, resuspend and count.
[0070] 2.3. PEG-mediated cell fusion 1) Spleen cells: SP2 / 0 cells were mixed at a ratio of 5:1, centrifuged, and the supernatant was discarded; 2) Slowly add preheated 50% PEG dropwise over 1 minute at 37℃, mix gently, and incubate precisely for 90 seconds; 3) Gradually add serum-free culture medium to terminate the PEG fusion process, then centrifuge and discard the supernatant; 4) Resuspend the cells in HAT selective complete medium, add 100 μL / well to a 96-well culture plate with a pre-laid feeder layer, and incubate statically in a 37°C CO2 incubator.
[0071] 2.4. First round of hybridoma positive screening (initial screening after fusion) 1) Replace half of the HAT medium on day 5 of fusion to discard unfused myeloma cells and spontaneously apoptotic spleen cells; 2) On days 8-10 after fusion, observe the cell clones under a microscope. When the clones grow to 1 / 10 of the area at the bottom of the well, aspirate 50 μL of cell supernatant. 3) Using the aforementioned indirect ELISA to detect specific antibodies in the supernatant, the OD value was significantly higher than that of the negative wells marked as positive hybridoma wells; 4) Transfer all ELISA-positive cells to 24-well plates for expanded culture.
[0072] 2.5. 24-well plate culture expansion detection 1) Transfer the selected positive well cells to 24-well plates for expanded culture; 2) The aforementioned indirect ELISA was used to detect specific antibodies in the supernatant, and the positive hybridoma wells were confirmed again; 2.6. Limiting dilution clonal screening 1) Mix positive hybridoma cells in a 24-well plate by pipetting and counting; then serially dilute to low cell density; 2) Pre-coat the 96-well plates with a feeder layer, add diluted cell suspension to each well to ensure an average of 0.5 to 1 cell per well; 3) After 7 days of culture, the single-clone colony wells were labeled under a microscope, and the supernatant was aspirated for ELISA to screen the anti-Avastin positive wells. 4) Collect positive monoclonal cells from the rescreening, expand their culture, and conduct a second round of cloning.
[0073] 2.7. Re-cloning and screening 1) Repeat the limiting dilution procedure and perform single-cell plating culture again; 2) All monoclonal well supernatants were positive by ELISA, with no negative wells, indicating a stable hybridoma line secreting anti-Avastin antibody; 3) Collect all stable positive monoclonal cell lines, expand their culture, and collect the cell supernatant for later use.
[0074] 3. Experimental Results 1) In the first round of hybridoma positive screening, a total of 31 wells with high positive values were selected. The specific results are as follows: Table 3. Results of hybridoma positive screening
[0075] Cells were transferred to 24-well plates for expanded culture, and the supernatant was collected for ELISA detection. The results showed that the supernatant collected from wells 1B9, 5F12, 6H3, 7F12, 7H1, 8G2, 10G5, 11E2, 12B12, and 12E9 had high positive values, and the first subcloning screening was performed.
[0076] Table 4 Subcloning Screening Results
[0077] The cells with high positive rates were limitedly diluted and cultured in 96-well plates. The supernatant was collected and analyzed by ELISA. Wells with high OD values were transferred to 24-well plates for further culture. The supernatant was then analyzed, and the results showed that cell clones of types 1B9B2, 7F12A8, 8G2H6, 10G5G5, 11E2C10, and 12B12E10 had lower numbers and relatively higher OD values.
[0078] Table 5 Results of 24-well plate culture expansion.
[0079] The cells from the above 6 wells were subjected to secondary subclonal screening. Wells 8G2H6A7 and 12B12E10A5, which had single clones and high OD values, were selected, expanded for culture, and cell supernatants were collected.
[0080] Table 6 Results of Secondary Subcloning Screening
[0081] Example 4: Preparation and Purification of Ascites Fluid 1. Experimental Materials 1) Domestic adjuvant for ascites (Suzhou Bio-Long Technology Co., Ltd., Product No.: KX0210048) 2) 6-8 week old SPF-grade female BALB / c mice (Beijing Vital River Laboratory Animal Technology Co., Ltd.) 3) Protein A / G chromatography medium (4FF) pre-packed column (Suzhou Bio-Long Technology Co., Ltd., item number: BDTL0021Z) 2. Experimental Methods 2.1 Ascites preparation 1) Mouse pretreatment Each BALB / c mouse was injected intraperitoneally with 0.4 mL of domestically produced ascites-specific adjuvant and fed normally for 7–14 days.
[0082] 2) Hybridoma cell preparation Take the amplified hybridoma cells, centrifuge at 500 g for 5 min, and discard the culture medium; wash the cells twice with sterile PBS to completely remove FBS; count with trypan blue, if viable cells are ≥90%, adjust the cell concentration to 1×10⁻⁶ cells with sterile PBS. 6 0.2 mL.
[0083] 3) Intraperitoneal inoculation of cells Each pretreated mouse was injected intraperitoneally with 0.2 mL of cell suspension (1 × 10⁶ cells per mouse). 6 Cells), each group of cells was inoculated into 2-3 mice.
[0084] 4) Observation and collection of ascites fluid Observe the abdomen and body weight of mice daily starting from day 5 after inoculation; collect ascites when the mouse abdomen is significantly distended, the skin is taut, and the movement is sluggish (7-14 days).
[0085] Temporary collection: Insert an 18G needle into the lower part of the abdominal cavity and collect ascites aseptically; the collection can be repeated 2-3 times at 2-3 day intervals; Terminal collection: Mice were euthanized by cervical dislocation, the abdominal wall was cut open, and all ascites fluid was aspirated using a dropper.
[0086] 5) Clarify the ascites fluid to obtain the ascites antibody stock solution. Collect ascites fluid and centrifuge at 3000 r / min for 10 min at 4℃ to remove red blood cells, cell precipitate, and fat layer; aspirate the clear, pale yellow ascites fluid in the middle and filter it through a 0.22 μm filter for sterilization, which is the ascites fluid antibody stock solution.
[0087] 2.2 Purification 1) Pre-processing of samples Take the antibody stock solution and add 1 M Tris-HCl at a volume ratio of 10:1 to adjust the sample pH to 7.2–8.0; centrifuge at 12000 g for 15 min at 4℃ to remove lipid and protein precipitates; filter through a 0.45 μm filter membrane to prevent impurities from clogging the chromatography column.
[0088] 2) Chromatography column equilibration Preload a Protein A / G gravity column, discard the 20% ethanol stock solution; add 5 column volumes of PBS equilibration buffer, allow to drain naturally, repeat twice to completely remove ethanol.
[0089] 3) Sample loading and combination Slowly load the pretreated antibody stock solution onto the column; collect the effluent, and repeat the loading once to improve IgG binding efficiency; incubate at room temperature or 4°C for 30 min to allow the IgG Fc fragment to fully bind to Protein A / G ligands.
[0090] 4) Washing removes impurities and proteins. Wash with 10 column volumes of PBS equilibration buffer to remove unbound proteins; optional high-salt washing (0.5 M NaCl-PBS) can further remove non-specifically adsorbed proteins and reduce background; continue washing until the eluent OD is reached. 280 Close to baseline, with no protein spikes.
[0091] 5) Acidic elution of specific IgG Prepare 0.1 M glycine-HCl pH 3.0 elution buffer; pre-add 50 μL of 1 M Tris pH 9.0 neutralization buffer to a 1.5 mL centrifuge tube; add 0.5 column volumes of elution buffer in fractions, collecting the elution fractions in segments; immediately after collecting each tube, gently invert to neutralize and bring the pH back to neutral. Measure the OD of each tube using a UV spectrophotometer. 280 The combined protein-positive elution fractions are the crude purified IgG.
[0092] 6) Dialysis desalting and replacement buffer The combined antibody eluent was placed in a 30 kDa dialysis bag and dialyzed with sterile PBS at 4°C. The dialysate was changed every 6 hours, and the dialysate was dialyzed for 24 hours to completely remove glycine and low molecular weight impurities. After elution, the column was rinsed with 5 column volumes of PBS. The column was then soaked in 20% ethanol-PBS and stored in a sealed container at 4°C.
[0093] 7) Concentration determination Protein concentration was measured using a micro-ultraviolet spectrophotometer.
[0094] 3. Experimental Results The detection concentrations of 8G2H6A7 antibody and 12B12E10A5 antibody were 2.02 mg / ml and 2.16 mg / ml, respectively.
[0095] Experiment 5: Combination Ability Test 1. Experimental Materials Avastin F(ab)'2 (Beijing Chengyi Biotechnology Co., Ltd.); 2) ELISA detection system: Coating solution (self-prepared), PBST washing solution (self-prepared), blocking solution (self-prepared), HRP-labeled goat anti-mouse IgG secondary antibody (Beijing Yiqiao Shenzhou Technology Co., Ltd., catalog number: SSA006), TMB chromogenic solution (self-prepared), stop solution (self-prepared). 2. Experimental Methods 1) Wrapped Add 100 μL of coating buffer (Avastin F(ab)'2, final concentration 1 μg / mL) to each well of a 96-well microplate and coat overnight at 4°C.
[0096] 2) Closed Wash 3 times with PBST for 3 min each time; add 300 μL of 2% skim milk blocking buffer to each well and incubate at room temperature for 1 h, then wash the plate 3 times. 3) Sample incubation The 8G2H6A7 antibody and the 12B12E10A5 antibody were serially diluted 3-fold from 2000 ng / ml to 0.034 ng / ml, and a blank control group (PBST) was set up, with 100 μL per well. Incubate at room temperature for 2 h.
[0097] 4) Secondary antibody incubation Wash the plate 3 times; after washing, add HRP-labeled goat anti-mouse IgG secondary antibody: 100 μL / well, and incubate at room temperature for 1 h.
[0098] 5) Color development Wash the plate 3 times; add 100 μL of TMB colorimetric solution per well and develop the color at room temperature in the dark for 20 min.
[0099] 6) Termination and reading The reaction was terminated with 50 μL of 2 M H2SO4, and the OD value was read at 450 nm using an ELISA reader.
[0100] 3. Experimental Results The test results showed that both antibodies exhibited good binding ability, with a sensitivity exceeding 1 ng / ml. Detailed results are shown in the table below.
[0101] Table 7 Results of Antibody Binding Ability Test
[0102] Note: The above values are OD values.
[0103] Figure 2 The pairing results for the 12B12E10A5 antibody; Figure 3 The pairing results are for the 8G2H6A7 antibody.
[0104] Example 6 Specificity Detection 1. Experimental Materials Avastin F(ab)'2 (Beijing Chengyi Biotechnology Co., Ltd.); Human blank plasma (Huizhiheyuan Biotechnology (Suzhou) Co., Ltd., catalog number: 032A15.25), Monkey blank plasma (Huizhiheyuan Biotechnology (Suzhou) Co., Ltd., catalog number: 032B15.25), Atezolizumab PDL1 (Roche), Bevacizumab Avastin (Roche); 2) ELISA detection system: coating solution (self-prepared), PBST washing solution (self-prepared), blocking solution (self-prepared), HRP-labeled goat anti-mouse IgG secondary antibody (Beijing Yiqiao Shenzhou Technology Co., Ltd., catalog number: SSA006), TMB chromogenic solution (self-prepared), and stop solution (self-prepared).
[0105] 2. Experimental Methods 1) Wrapped Avastin F(ab)'2, Avastin, and PDL1 were diluted to 0.5 μg / mL using coating buffer. Human blank plasma and monkey blank plasma were diluted 200 times. 100 μL / well was added to a 96-well microplate and coated overnight at 4°C.
[0106] 2) Closed Wash 3 times with PBST for 3 min each time; add 300 μL of 2% skim milk blocking buffer to each well and incubate at room temperature for 1 h, then wash the plate 3 times. 3) Sample incubation Dilute 8G2H6A7 and 12B12E10A5 to 500 ng / ml, 100 μL per well, and incubate at room temperature for 2 h.
[0107] 4) Secondary antibody incubation Wash the plate 3 times; after washing, add HRP-labeled goat anti-mouse IgG secondary antibody: 100 μL / well, and incubate at room temperature for 1 h.
[0108] 5) Color development Wash the plate 3 times; add 100 μL of TMB colorimetric solution per well and develop the color at room temperature in the dark for 20 min.
[0109] 6) Termination and reading The reaction was terminated with 50 μL of 2 M H2SO4, and the OD value was read at 450 nm using an ELISA reader.
[0110] 3. Experimental Results The test results showed that the two antibodies were unique antibodies, specifically binding to Avastin and Avastin F(ab)'2, but not to human plasma, monkey plasma, or isotype antibody (PDL1). Detailed results are shown in Table 8 below.
[0111] Table 8 Antibody Specificity Detection
[0112] Example 7 Neutralization Activity Detection 1. Experimental Materials VEGF (Beijing Chengyi Biotechnology Co., Ltd.); Bevacizumab (Avastin) (Roche) 2) ELISA detection system: Coating solution (self-prepared), PBST washing solution (self-prepared), blocking solution (self-prepared), mouse anti-human IgG1-Fc HRP secondary antibody (Beijing Yiqiao Shenzhou Technology Co., Ltd., catalog number: 10702-MM01T), TMB chromogenic solution (self-prepared), stop solution (self-prepared). 2. Experimental Methods 1) Wrapped Dilute VEGF to 1 μg / mL with coating buffer, add 100 μL / well to a 96-well microplate, and coat overnight at 4°C.
[0113] 2) Closed Wash 3 times with PBST for 3 min each time; add 300 μL of 2% skim milk blocking buffer to each well and incubate at room temperature for 1 h, then wash the plate 3 times. 3) Sample incubation 8G2H6A7 and 12B12E10A5 were serially diluted 2-fold from 2000 ng / ml to 15.625 ng / ml, and 50 μL / well was added to each well of a microplate. Avastin was also diluted to 10 ng / ml and 50 μL / well was added to each well of the microplate. The plates were incubated at room temperature for 2 h.
[0114] 4) Secondary antibody incubation Wash the plate 3 times; after washing, add mouse anti-human IgG1-Fc HRP secondary antibody: 100 μL / well, and incubate at room temperature for 1 h.
[0115] 5) Color development Wash the plate 3 times; add 100 μL of TMB colorimetric solution per well and develop the color at room temperature in the dark for 20 min.
[0116] 6) Termination and reading The reaction was terminated with 50 μL of 2 M H2SO4, and the OD value was read at 450 nm using an ELISA reader.
[0117] 3. Experimental Results The test results showed that when the concentration of the two antibodies was 500 ng / ml, the inhibition rate could reach more than 50%, indicating good neutralizing activity. Detailed results are shown in Table 9 below.
[0118] Table 9. Antibody Neutralization Activity Detection
[0119] Example 8 Antibody Identification 1. Experimental Materials ELISA kit for identifying mouse monoclonal antibody Ig classes / subclasses (Suzhou Bio-Long Technology Co., Ltd., Catalog No.: BF06001) 2. Experimental Methods 2.1 Antibody subtype identification 1) First, bring the kit to room temperature, then use pure water to prepare the cleaning solution to the working concentration (1 part concentrated cleaning solution plus 19 parts pure water).
[0120] 2) Remove the ELISA plate. Each sample requires 6 wells: 6 wells for the positive control and 6 wells for the negative control. Store any excess in a resealable bag, remembering to include a desiccant.
[0121] 3) Add 50 μl of sample diluent to each well of the sample detection plate. Then add 50 μl of cell culture supernatant (or specifically affinity-purified antibody) to 6 wells of the ELISA plate. Add 100 μl to 6 wells of the positive control and negative control plates, without adding sample diluent. Cover with sealing film and incubate at 37°C for 30 minutes.
[0122] 4) Discard the liquid in the plate, wash the plate 5 times, then pat dry on absorbent material without shedding fibers or machine wash 5 times. Add 100 μl of each of the 6 wells containing one of the 6 enzyme-labeled secondary antibodies. Repeat the same process for the general positive and negative control wells. Mark the wells on the sample loading diagram or on the ELISA plate. Cover with sealing film and incubate at 37°C for 30 minutes.
[0123] 5) Absorb the liquid inside the plate, wash the plate 5 times, then pat dry on absorbent material that does not shed fibers or machine wash 5 times. Add 50μl each of developer A and developer B to each well, replace with a new sealing film, attach the plate, and develop at 37℃ in the dark for 20 minutes.
[0124] 6) After stopping the reaction with the reaction stop solution (50 μl per well), use a microplate reader to measure the wavelength at 450 nm and the reference wavelength at 630 nm. By referring to the enzyme-labeled secondary antibody corresponding to the high value well, you can know the Ig class or subclass of this sample.
[0125] 2.2 Antibody Sequencing The antibody was sent to a third-party company for sequencing of the variable region.
[0126] 3. Experimental Results 3.1 Subtype Identification Results The two antibody subtypes were identified as IgG1 and Igκ.
[0127] Table 10 Antibody subtype identification results
[0128] 3.2 Antibody Sequencing The amino acid and base sequences of the variable regions of the heavy and light chains of the 8G2H6A7 antibody are shown in Table 11 below.
[0129] Table 11. Amino acid and base sequences of the variable regions of the heavy and light chains of the 8G2H6A7 antibody.
[0130] The amino acid and base sequences of the variable regions of the heavy and light chains of the 12B12E10A5 antibody are shown in Table 12 below.
[0131] Table 12. Amino acid and base sequences of the variable regions of the heavy and light chains of the 12B12E10A5 antibody.
[0132] The above description of the embodiments is only for understanding the method and core ideas of the present invention. It should be noted that those skilled in the art can make various improvements and modifications to the present invention without departing from the principles of the invention, and these improvements and modifications will also fall within the protection scope of the claims of the present invention.
Claims
1. An antibody or antigen-binding fragment that recognizes bevacizumab or a fragment thereof, characterized in that, The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region have… a) The amino acid sequences of heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 in the heavy chain variable region as shown in SEQ ID NO:1; The amino acid sequences are as shown in SEQ ID NO:2, specifically the light chain CDR1, CDR2, and CDR3 in the light chain variable region; or b) The amino acid sequences of heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 in the heavy chain variable region as shown in SEQ ID NO:11; The amino acid sequences are shown in SEQ ID NO:12, specifically light chain CDR1, light chain CDR2, and light chain CDR3 in the light chain variable region. Preferably, the bevacizum fragment is selected from bevacizum F(ab)'2.
2. The antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in claim 1, characterized in that, The amino acid sequences of the heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 are shown in SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, respectively, and the amino acid sequences of the light chain CDR1, light chain CDR2, and light chain CDR3 are shown in SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, respectively; or The amino acid sequences of the heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 are shown in SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, respectively, and the amino acid sequences of the light chain CDR1, light chain CDR2, and light chain CDR3 are shown in SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, respectively. Preferably, the heavy chain variable region of the antibody or antigen-binding fragment recognizing bevacizumab or its fragment has an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:1, and the light chain variable region of the antibody or antigen-binding fragment recognizing bevacizumab or its fragment has an amino acid sequence as shown in SEQ ID NO:2 or an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:2; or The heavy chain variable region of the antibody or antigen-binding fragment that recognizes bevacizumab or its fragments has an amino acid sequence as shown in SEQ ID NO:11 or an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:11, and the light chain variable region of the antibody or antigen-binding fragment that recognizes bevacizumab or its fragments has an amino acid sequence as shown in SEQ ID NO:12 or an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:
12.
3. An antibody derivative, characterized in that, The antibody derivative is formed by direct or indirect coupling of a detectable marker with an antibody or antigen-binding fragment that recognizes bevacizum or a fragment thereof as described in any one of claims 1-2.
4. Hybridoma cells, characterized in that, The hybridoma cells produce antibodies or antigen-binding fragments that recognize bevacizum or fragments thereof as described in any one of claims 1-2.
5. A polynucleotide molecule, characterized in that, The polynucleotide molecule encodes an antibody or antigen-binding fragment that recognizes bevacizum or a fragment thereof as described in any one of claims 1-2.
6. A carrier, characterized in that, The carrier contains the polynucleotide molecule as described in claim 5.
7. A host cell or a population of cells containing a host cell, characterized in that, The host cell comprises an antibody or antigen-binding fragment that recognizes bevacizum or a fragment thereof as described in any one of claims 1-2, a polynucleotide molecule as described in claim 5, or a vector as described in claim 6.
8. A product for detecting or quantifying bevacizum or fragments thereof, characterized in that, The product contains an antibody or antigen-binding fragment that recognizes bevacizum or a fragment thereof as described in any one of claims 1-2, an antibody derivative as described in claim 3, a hybridoma cell as described in claim 4, a polynucleotide molecule as described in claim 5, a vector as described in claim 6, and a host cell or a cell population containing a host cell as described in claim 7. Preferably, the product is selected from reagent kits, test strips, reagents, and chips; Preferably, the kit is selected from ELISA detection kits, immunofluorescence detection kits, FACS kits, Western Blot kits, IHC detection kits, and ICC kits.
9. Any one of the following methods: (1) An antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in any one of claims 1-2, characterized in that, The method includes the following steps: culturing the hybridoma cells of claim 4, or the host cells of claim 7, or a population of host cells containing the hybridoma cells of claim 7; (2) A method for detecting or quantifying bevacizum or a fragment thereof in a sample, characterized in that the method comprises the following steps: contacting the sample to be tested with an antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in any one of claims 1-2, or contacting the sample to be tested with an antibody derivative as described in claim 3, or contacting the sample to be tested with bevacizum or a fragment thereof as described in claim 8 to detect or quantify bevacizum or a fragment thereof, to form an antigen-antibody complex, and detecting the antigen-antibody complex; (3) A method for preparing the host cell or host cell population containing the present invention as claimed in claim 7, characterized in that the method comprises the following steps: introducing the polynucleotide molecule of claim 5 or the vector of claim 6 into the host cell; (4) A method for blocking the binding of bevacizumab to VEGF in vitro, characterized in that the method includes using an antibody or antigen-binding fragment that recognizes bevacizumab or a fragment thereof as described in any one of claims 1-2, an antibody derivative as described in claim 3, or a product for detecting or quantifying bevacizumab or a fragment thereof as described in claim 8 to block the binding of bevacizumab to VEGF. (5) A method for in vitro detection of bevacizumab antibody or fragment antibody for non-disease diagnosis purposes, characterized in that the method comprises: contacting a sample with bevacizumab or fragment to form an immune complex; and detecting the presence or content of the immune complex; wherein the method uses the antibody or antigen-binding fragment for recognizing bevacizumab or fragment as described in any one of claims 1-2, the antibody derivative as described in claim 3, and the product for detecting or quantifying bevacizumab or fragment as described in claim 8 as a standard positive control.
10. Any of the following applications: (1) The use of the antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in any one of claims 1-2, the antibody derivative as described in claim 3, the hybridoma cell as described in claim 4, the polynucleotide molecule as described in claim 5, the vector as described in claim 6, the host cell or cell population containing the host cell as described in claim 7 in the preparation of a product for detecting or quantifying bevacizum or a fragment thereof; (2) The use of the antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in any one of claims 1-2, the antibody derivative as described in claim 3, the hybridoma cell as described in claim 4, the polynucleotide molecule as described in claim 5, the vector as described in claim 6, the host cell or cell population containing the host cell as described in claim 7, and the product for detecting or quantifying bevacizum or a fragment thereof as described in claim 8 in detecting or quantifying bevacizum or a fragment thereof. (3) The use of the antibody or antigen-binding fragment for recognizing bevacizum or its fragments as described in any one of claims 1-2, the antibody derivative as described in claim 3, the hybridoma cell as described in claim 4, the polynucleotide molecule as described in claim 5, the vector as described in claim 6, the host cell or cell population containing the host cell as described in claim 7, and the product for detecting or quantifying bevacizum or its fragments as described in claim 8 in the preclinical pharmacological evaluation, pharmacokinetic evaluation and / or immunogenicity evaluation of bevacizum monoclonal antigen research drug, biosimilar or modified derivative; (4) The use of the antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in any one of claims 1-2, the antibody derivative as described in claim 3, the hybridoma cell as described in claim 4, the polynucleotide molecule as described in claim 5, the vector as described in claim 6, the host cell or cell population containing the host cell as described in claim 7, and the product for detecting or quantifying bevacizum or a fragment thereof as described in claim 8 in the preparation of a reagent for blocking the binding of bevacizum to VEGF. (5) The use of the antibody or antigen-binding fragment for recognizing bevacizum or a fragment thereof as described in any one of claims 1-2, the antibody derivative as described in claim 3, and the product for detecting or quantifying bevacizum or a fragment thereof as described in claim 8 in the preparation of a product for detecting or quantifying bevacizum or a fragment thereof, characterized in that, The antibody or antigen-binding fragment that identifies bevacizum or a fragment thereof, antibody derivative, or product for detecting or quantifying bevacizum or a fragment thereof is used as a positive control.
